New pill takes on tough blood cancers in first human trial
NCT ID NCT06590961
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests an experimental oral drug called UBX-303061 in 94 adults with B-cell blood cancers (like certain lymphomas and leukemias) that have come back or not responded to at least two prior treatments. The main goals are to check safety, find the right dose, and see if the drug shows any anti-cancer activity. It is a first-in-human study, so results are very preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UBX-303061 (oral drug)
What this could lead to
If successful, this could point toward a new oral treatment option for certain blood cancers that have stopped responding to other therapies.
What could go wrong
This is a very early, first-in-human trial with only 94 participants. The drug may not prove safe or effective, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AidPort
NOT_YET_RECRUITINGGrodzisk Wielkopolski, Wielkopolskie Voivodeship, 62-065, Poland
-
Asan Medical Center
RECRUITINGSeoul, Seoul, 05505, South Korea
-
Gabrail Cancer Center
RECRUITINGCanton, Oklahoma, 44718, United States
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
MICS Centrum Medyczne Toruń
NOT_YET_RECRUITINGTorun, Kuyavian-Pomeranian Voivodeship, 87-100, Poland
-
Pratia, MTZ Clinical Research
NOT_YET_RECRUITINGWarsaw, Mazowieckie Voivodeship, 02-172, Poland
-
Pratia, Oncology Katowice
NOT_YET_RECRUITINGKatowice, Silesian Voivodeship, 40-519, Poland
-
Samsung Medical Center
RECRUITINGSeoul, Seoul, 06351, South Korea
-
The Catholic University of Korea, Seoul St. Mary's Hospital
RECRUITINGSeoul, Seoul, 06591, South Korea
-
The Catholic University of Korea, Yeouido St. Mary's Hospital
RECRUITINGSeoul, Seoul, 07345, South Korea
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States